Document:

Letter Agreement dated June 26, 2007

 Exhibit 10.61 
  

					
		  		  	BAYER HEALTHCARE AG
		  		  	13342 LEVERKUSEN, GERMANY
		  		  	JUNE 25, 2007

 Ted W. Love, M.D. 
 Chairman & CEO 
 Nuvelo, Inc. 
 201 Industrial
Road, Suite 310 
 San Carlos, CA 94070 
  

			
	RE:	 	License and Collaboration Agreement, dated as of January 4, 2006 (the “Agreement”), by and between Nuvelo, Inc. (“Nuvelo”) and Bayer Healthcare AG
(“Bayer”)

 Dear Dr. Love: 
 This letter, when signed by Nuvelo, will constitute the agreement between Nuvelo and Bayer regarding the termination of the Agreement. All capitalized terms in this letter will have the meanings provided in the
Agreement, unless they are otherwise defined in this letter. 
 1. Subject to the terms of this letter, Bayer hereby terminates the
Agreement, effective June 30, 2007, pursuant to Section 15.4 of the Agreement (“Bayer Termination; Effects of Termination”). Except as specifically provided to the contrary in this letter, the effects of termination will
be as provided in Section 15.4 of the Agreement. 
 2. Subject to the terms of this letter, including without limitation Bayer’s
payment of the fee set forth in Paragraph 3 of this letter, Nuvelo hereby waives its rights under Section 15.4 (vii) to require Bayer: (a) to provide Nuvelo twelve (12) months’ written notice of termination; (b) to continue
to reimburse Nuvelo for Bayer’s share of Development Expenses under Section 4.7 of the Agreement in conducting Global Development Programs approved by the JSC prior to the date of Bayer’s notice of termination to Nuvelo; and
(c) to pay Nuvelo the milestone payment provided in Section 8.2(a)(vii) of the Agreement upon Nuvelo’s initiation of a Global Development Program for Licensed Product that is a Phase 2 Clinical Trial in a stroke indication.

 3. Within thirty (30) days of the date of this letter, Bayer will pay Nuvelo the non-refundable sum of Fifteen Million Dollars
(US$15,000,000) in immediately available funds, by electronic transfer to a Nuvelo bank account designated in writing by Nuvelo. 
 4. Within
thirty (30) days of June 30, 2007, Nuvelo and Bayer will submit to each other written statements showing Development Expenses incurred during that calendar quarter in connection with Global Development Programs as provided in
Section 4.7 of the Agreement. Nuvelo and Bayer will reconcile those statements, and the appropriate amount will be paid by the party owing such amount, as provided in Section 4.7. 

 5. Subject to the terms of this letter, Nuvelo hereby grants to Bayer a one-time, non-transferable
exclusive option (the “Option”) to re-acquire right to develop and commercialize alfimeprase outside of the United States following (a) Nuvelo’s initiation of a Pivotal Trial (as defined below) for alfimeprase in the stroke
indication (the “Pivotal Stroke Trial”) or (b) Nuvelo’s public announcement that it is discontinuing further development of alfimeprase in the stroke indication. Bayer may exercise the Option by delivery to Nuvelo of written
notice of exercise, together with a non-refundable payment of Fifteen Million Dollars ($15,000,000) in immediately available funds (the “Option Exercise Fee”), within thirty (30) days (the “Notice Period”) after Nuvelo
provides to Bayer the following: If Nuvelo has initiated the Pivotal Stroke Trial, the Notice Period will begin when Nuvelo has provided Bayer with access to the data tables from the CARNEROS-1 stroke trial (the “CARNEROS-1 Trial”) within
30 days of trial completion, the protocol for the Pivotal Stroke Trial, and a certificate confirming that Nuvelo has obtained sufficient clearance from applicable US or EU Regulatory Authorities to initiate the Pivotal Stroke Trial. If Nuvelo has
publicly announced its discontinuance of development of alfimeprase in the stroke indication, the Notice Period will begin when Nuvelo has provided Bayer with access to the data tables from the CARNEROS-1 Trial and a copy of Nuvelo’s public
announcement of its discontinuance of development of alfimeprase in the stroke indication. 
 The Option Exercise Fee shall be paid by
electronic transfer to a Nuvelo bank account designated in writing by Nuvelo. If Bayer does not exercise the Option by the end of the Notice Period, Bayer shall have no further right or interest of any kind relating to alfimeprase. If Bayer does
exercise the Option prior to the end of the Notice Period, Bayer and Nuvelo shall execute a new License and Collaboration Agreement on the same terms as the Agreement, except that the Effective Date shall be the date of Bayer’s exercise of the
Option, there shall not be an upfront payment (other than payment of the Option Exercise Fee) or the milestone payment provided for in Section 8.2(a)(vii) of the Agreement (Initiation a Global Development Program for a Licensed Product that is
a Phase 2 Clinical Trial in a stroke indication), and Bayer shall not be responsible for any Development Expenses incurred after June 30, 2007 and prior to the new Effective Date. 
 For purposes of this letter, “Pivotal Trial” shall mean a Clinical Trial commenced after the conclusion of the CARNEROS-1 Trial, on sufficient
numbers of subjects that, if the defined end-points are met, is designed (and agreed to by the FDA, or other EU Regulatory Authorities) to establish that alfimeprase is safe and efficacious for the treatment of a stroke indication, and to define
warnings, precautions and adverse reactions that are associated with the drug in the dosage range to be prescribed, and which provides pivotal data supporting Regulatory Approval of alfimeprase and that satisfy the requirements of 21 CFR 321.21(c),
or its successor regulation, or an equivalent foreign clinical trial. 

 This letter agreement summarizes all claims that either party may have against the other. Payments made
by Bayer and the exclusive option granted by Nuvelo are full and final settlement of all claims one party may have against the other arising out of the Agreement. 
 If this letter accurately reflects your understanding of the our agreement to terminate the Agreement, please sign and date a copy of this letter in the space indicated below and return it to me. 
  

	
	Sincerely,
	
	 /s/ Gunnar Riemann
  
 Gunnar Riemann

  

			
	 AGREED AND ACCEPTED:

	
	 NUVELO, INC.

		
	 By
	 	 /s/ Ted W. Love

		 	Ted W. Love
		 	Chairman & CEO

  

			
		
	 Date:
	 	 June 26, 2007Employment Agreement

 Exhibit 10.1 
 DIVERSA CORPORATION 
 June 20, 2007 
 Mr. Carlos Riva 
 P.O. Box 137 
 Hamilton, MA 01936 
 Dear Carlos: 
 We
are pleased to confirm the compensation agreement between you and Diversa Corporation (the “Company”). In consideration of the covenants and agreements set forth below, the Company hereby employs you, and you hereby agree to
be employed by the Company, on the following terms and conditions: 
 1. Term. This letter agreement (the
“Agreement”) shall become effective as of the closing date of the merger of Celunol Corp. (“Celunol”) with one of the Company’s subsidiaries (“Merger Sub”) contemplated by
the Agreement and Plan of Merger and Reorganization entered into as of February 12, 2007 among the Company, Celunol and Merger Sub (such closing date, the “Effective Date”) and shall continue until it is terminated by
you or the Company in accordance with, and subject to the obligations set forth in, the provisions of Section 5 below (the “Term”). 
 2. Duties and Responsibilities. During the Term of this Agreement, you shall have, and you agree to carry out to the best of your ability, the duties and responsibilities of President and Chief Executive
Officer. You shall have such executive responsibilities and duties as are assigned by the Board of Directors of the Company (the “Board”) and are consistent with the positions of President and Chief Executive Officer. In the
performance of your duties and responsibilities hereunder, you shall regularly report to the Board. You agree to devote your full business time, attention and energies to the business and interests of the Company during the Term of this Agreement
and you will not accept any outside position without the prior written consent of the Board, except that you may serve on up to a maximum of two boards of directors provided that you have approval of the Board’s Compensation Committee and
provided that your time spent in such service is reasonable and does not detract from the performance of your duties to the Company. You warrant that you are free to enter into and fully perform this Agreement and are not subject to any employment,
confidentiality, non-competition or other agreement which would restrict your performance under this Agreement. You shall, subject to election and re-election by the Company’s shareholders in accordance with the Company’s Articles of
Incorporation and Bylaws, be appointed to serve in the class of Board directors whose terms expire at the Company’s 2007 annual stockholders’ meeting and nominated to serve in the class of directors to be elected at the 2007 annual
stockholders’ meeting, or, if the 2007 annual stockholders’ meeting has already occurred at the time of your appointment to the Board, you will be appointed to serve in the class of directors whose terms expire at the Company’s 2010
annual stockholders’ meeting. In connection with the termination of your employment by the Company as President and Chief Executive Officer, you shall resign from the Board effective simultaneously with the effective date of such termination.

 Carlos Riva 
 June 20,
2007 
  

 You shall fulfill your duties and responsibilities to the Company hereunder primarily from the
Company’s corporate office located in Dedham, MA, or, in the event the Company relocates its principal office, from such future location, provided that the Company shall not require you to maintain your principal place of work in any location
that is more than fifty (50) miles outside of Boston, MA without your prior consent, provided, however that the Company may from time to time require you to travel temporarily to other locations in connection with the Company’s business.

 3. Compensation and Benefits. Subject to your adherence to all of your responsibilities under this Agreement, during the
Term of this Agreement you shall be entitled to receive the following compensation and benefits. 
 (a) Base Salary. Commencing
on the Effective Date, and during the Term of this Agreement, the Company will pay you a base salary at the monthly rate of $38,333.34 (“Base Salary”), minus withholdings as required by law or other deductions authorized by
you, which amount shall be paid to you in periodic installments in accordance with the Company’s payroll practices then in effect. Your Base Salary shall be subject to review on an annual basis by the Board of Directors or its Compensation
Committee. 
 (b) Incentive Bonus. For each calendar year during the Term of this Agreement, you will be eligible to receive an
annual performance-based incentive bonus, based upon the achievement of milestones set by the Board, of up to a maximum of sixty percent (60%) of the Base Salary earned during such period. Any incentive bonus earned by you will be paid in
accordance with the Company’s standard practices and policies regarding bonuses. The milestones required to achieve payment of the bonus will be established by the Board of Directors, after consultation with you. 
 (c) Benefits. During the Term of this Agreement, you shall be entitled to participate, to the extent you are otherwise eligible, in all
group insurance programs or other fringe benefit plans which the Company shall make available to similarly situated employees. The Company may alter, modify, add to or delete its employee benefit plans at any time as it, in its sole judgment,
determines to be appropriate, without recourse by you. 
 (d) Vacation. You will be entitled to four (4) weeks of vacation
per calendar year, in accordance with the Company’s vacation policy as in effect from time to time. 
 (e) Stock Options. Upon approval by the Board of Directors you will be granted, on the Effective Date, an option to purchase one million (1,000,000) shares of the Company’s common stock (the
“Option”) which shall vest over four (4) years for so long as you are employed by the Company on the designated vesting dates as follows: i) on the final day of the quarter of the calendar year first following the
fifteen month anniversary of the Effective Date, one-twelfth (1/12th) of the Option shares shall vest; and ii)
an additional 1/12th of the Option shares shall vest on the final day of each quarter of each calendar year
thereafter. 

 Carlos Riva 
 June 20,
2007 
  

 (f) Business Expense Reimbursement. The Company shall reimburse you for the travel,
entertainment and all other business related expenses reasonably incurred by you in the performance of your duties hereunder in accordance with the Company’s policies as in effect from time to time for senior executives. 
 4. Confidential and Proprietary Information; Restrictive Covenants; Non-solicitation; Indemnification. 
 (a) Covenant not to Compete. You acknowledge that by virtue of your employment pursuant to this Agreement, you will have access to valuable
trade secrets and other confidential business and proprietary information of the Company. Except with the prior written consent of the Board you will not, during your employment by the Company, engage in competition with the Company and/or any of
its Affiliates, either directly or indirectly in any manner or capacity, as adviser, principal, agent, affiliate, promoter, partner, officer, director, employee, stockholder, owner, co-owner, consultant, member of any association, or otherwise, in
any phase of the business of researching, developing, manufacturing, or marketing of products or services which are in the same field of use or which otherwise compete with the products or services or proposed products or services of the Company
and/or any of its Affiliates. For purposes of this Agreement, “Affiliate” means, with respect to any specific entity, any other entity that, directly or indirectly, through one or more intermediaries, controls, is controlled
by or is under common control with such specified entity. Except with the prior written consent of the Board, you shall not, during your employment by the Company and for a period of one (1) year thereafter (the “Restricted
Period”), engage in competition with the Company or any of its Affiliates, either directly or indirectly, as adviser, principal, agent, affiliate, promoter, partner, officer, director, employee, stockholder, owner, co-owner, consultant,
member of any association, or otherwise, in any phase of the business of the research, development, manufacturing, production, sales, or marketing of biofuels. 
 (b) Agreement not to Participate in Company’s Competitors. During any period during which you are receiving compensation or consideration from the Company, you will not acquire, assume, or
participate in, directly or indirectly, any position, investment, or interest known by you to be adverse or antagonistic to the Company, its business, or prospects, financial or otherwise, or in any company, person, or entity that is, directly or
indirectly, in competition with the business of the Company or any of its Affiliates. Ownership by you, as a passive investment, of less than two percent (2%) of the outstanding shares of capital stock of any corporation with one or more
classes of its capital stock listed on a national securities exchange or publicly traded on the Nasdaq Stock Market or in the over-the-counter market shall not constitute a breach of this paragraph. 
 (c) Non-solicitation. During the Restricted Period you shall not, either directly, or through others: (1) hire any individual who is
at that time, or who was during the one (1) year immediately prior thereto, an employee, consultant or independent contractor of the Company or any Affiliate; (2) solicit or attempt to solicit any individual who is at that time, or who was
during the one (1) year immediately prior thereto, an employee, consultant or independent contractor of the Company or any Affiliate to terminate his or her relationship with the Company or any Affiliate in order to become an employee,
consultant or independent 

 Carlos Riva 
 June 20,
2007 
  

 
contractor to or for any person or business entity; or (3) solicit or attempt to solicit the business of the Company or any Affiliate, investor, client,
customer, supplier, service provider, vendor, or distributor of the Company or any Affiliate that is at that time, or that was during the one (1) year immediately prior thereto, doing business with the Company or any Affiliate or listed on the
Company or any Affiliate’s investor, client, customer, supplier, service provider, vendor or distributor lists. 
 (d) Employee
Invention and Non-Disclosure Agreement. As a condition of employment, you agree to execute and abide by the Company’s standard Employee Invention and Non-Disclosure Agreement. 
 (e) Indemnification. The Company agrees to indemnify you against third party claims based upon, related to, or arising from your
performance of services pursuant to this Agreement in accordance with the Company’s Articles of Incorporation and Bylaws, and as required by law. 
 5. Termination. You and the Company shall be free to terminate this Agreement as follows and subject to the payment obligations set forth herein: 
 (a) By the Company for Cause. The Company shall have the right to terminate your employment hereunder at any time for
“Cause.” For purposes of this Agreement only, “Cause” shall be defined to include (1) material misconduct in the performance of your duties and responsibilities hereunder, (2) your material failure,
refusal or inability (other than for reasons of disability) to perform your duties and responsibilities hereunder or to carry out any lawful direction of the Board of Directors, (3) breach by you of a material term of this Agreement, the
Employee Invention and Non-Disclosure Agreement, or any other agreement between you and the Company, (4) conviction of or plea of nolo contendere to, a felony or other crime involving moral turpitude, or imprisonment for any crime;
provided, however, that in the event of a potential termination for Causes 2 or 3 above, such termination may not occur until at least thirty (30) days after the Company has provided you with a detailed written notice of the ground(s)
for the termination, and then only if you have failed to correct the behavior giving rise to such potential termination; (5) your material failure to comply with Company policies including but not limited to Equal Employment Opportunity and
Harassment policies, Professional Conduct policy, and/or Code of Business Conduct and Ethics policy; and (6) your violation of any statutory or fiduciary duty owed to the Company. Notwithstanding any other provision of this Agreement, in the
event of a termination for Cause pursuant to this paragraph, the Company shall only be obligated to pay you (i) your Base Salary through the date of your termination, (ii) your accrued but unused vacation, (iii) any earned, but
unpaid, performance bonus described in Section 3(b) with respect to the calendar year immediately preceding the year in which your employment is terminated, based on the achievement of the performance milestones established for such calendar
year in accordance with Section 3(b), as determined by the Board of Directors, and (iv) such other benefits and payments to which you may be entitled by law or pursuant to the benefit plans of the Company then in effect (collectively, the
“Accrued Obligations”). 

 Carlos Riva 
 June 20,
2007 
  

 (b) Death; Disability. Your employment hereunder shall terminate in the event of your
death and in the event that you shall be prevented, by illness, accident, disability or any other physical or mental condition (to be determined by means of a written opinion of a competent medical doctor chosen by mutual agreement of the Company
and you or your personal representative), from substantially performing your duties and responsibilities hereunder for one or more periods totaling ninety (90) days in any twelve (12) month period. In the event of a termination of your
employment pursuant to this paragraph, you or your estate, as applicable, shall be entitled to receive payment of the Accrued Obligations. 
 (c) Termination by the Company Other Than for Cause. The Company shall have the right to terminate your employment hereunder at any time other than for Cause. In the event of a termination by Company pursuant to this
paragraph, you shall be entitled to receive payment of the Accrued Obligations and the following severance pay and related benefits: 
 (i) the Company will pay you severance pay in the amount of your then-current Base Salary for a period of twelve (12) months after your termination date, minus required withholdings, which severance payments will be made to you
on the Company’s normal payroll cycle; 
 (ii) the Board of Directors or the Compensation Committee may elect to
pay to you a pro rated bonus for the year in which your employment is terminated, but any such payment shall be in the sole discretion of the Board of Directors or the Compensation Committee; 
 (iii) should you elect to continue your group health and dental insurance benefits in accordance with the provisions of COBRA
following the date of your termination, the Company shall pay the full premium for such health and dental insurance continuation benefits for a period of twelve (12) months after the termination date; and 
 (iv) notwithstanding the terms of any stock option grants and/or restricted stock awards, the vesting of all options to purchase
Company stock held by you will automatically accelerate such that, effective on the date of such termination, you will be deemed vested in the same number of option shares as if you had remained employed by the Company for a period of period of
twelve (12) months following the date of termination and all restricted stock held by you that would otherwise vest over the twelve (12) months following the date of termination shall automatically and immediately vest and no longer be
subject to forfeiture or a right to repurchase by the Company. 
 Your right to receive such severance pay, stock and/or option accelerated
vesting benefits, and related benefits as set forth in this paragraph 5(c) shall be contingent upon (x) your compliance with all of your obligations under this Agreement and the Employee Invention and Non-Disclosure Agreement, and (y) your
delivery to the Company of a fully effective general release of all claims against the Company and its affiliates in the form attached hereto as Exhibit A or in such other form as may be specified by the Company. 

 Carlos Riva 
 June 20,
2007 
  

 (d) Termination by You for Good Reason. In the event that you resign your employment
with Company at any time, by providing to the Company a written notice of resignation within sixty (60) days following an event constituting “Good Reason,” as that phrase is defined below, your resignation shall be
deemed to be a termination of your employment by the Company other than for Cause pursuant to paragraph 5(c) above, in which event both you and the Company shall have your respective rights and obligations in the event of such a termination. In the
event that you do not send the Company a written notice of resignation pursuant to this paragraph within sixty (60) days following an event constituting Good Reason, your rights under this paragraph 5(d) shall cease. For purposes of this
Agreement, the phrase “Good Reason” shall mean any of the following actions by the Company without your consent: (i) your demotion to a position other than President and Chief Executive Officer, or a material reduction in your duties
or responsibilities as described in Section 2 of this Agreement, (ii) a material reduction in your Base Salary, provided, however, that a reduction in your Base Salary shall not constitute Good Reason if it is made in connection with an
across-the-board reduction of all senior executives’ annual base salaries, (iii) material reduction of your ability to participate in the Company’s fringe and benefit plans, other than any reduction that is part of a general reduction
or other concessionary arrangement affecting all senior officers, (iv) the Company requires you to permanently relocate your office to a location outside the geographic area described in Section 2 of this Agreement; or (v) any other
conduct that constitutes a breach by the Company of a material term of this Agreement, or any other written agreement between the Company and you; provided that in the event of a termination for Good Reason, such termination may not occur
until at least thirty (30) days after you have provided the Company with a detailed written notice of the ground(s) for termination, and then only if the Company has failed to correct the behavior giving rise to such potential termination.

 (e) Termination by You for Any Other Reason. You shall have the right to terminate your employment hereunder at any time for
any reason not otherwise covered by paragraph 5(d) by providing ninety (90) days’ prior written notice to the Company. In the event of a termination by you pursuant to the preceding sentence, the Company shall only be obligated to pay you
the Accrued Obligations. The Company shall be obligated, however, to continue to pay your full compensation as described in Section 3 hereof up to and through the expiration of the ninety (90) day notice period. 
 6. Specific Performance. You recognize and agree that the Company’s remedy at law for breach of the Employee Invention and
Non-Disclosure Agreement would be inadequate, and further agree that, for breach of such provisions, the Company shall be entitled to seek injunctive relief and to enforce its rights by an action for specific performance. 
 7. Payment of Legal Fees; Certain Tax Issues. 
 (a) Legal Fees. The Company shall reimburse you for reasonable documented legal fees incurred by you in connection with the execution and negotiation of this Agreement, up to a maximum of $5,000.

 Carlos Riva 
 June 20,
2007 
  

 (b) Withholding. All payments made to you pursuant to this Agreement or otherwise in
connection with your employment shall be subject to the usual withholding practices of the Company and will be made in compliance with existing federal and state requirements regarding the withholding of tax. 
 (c) Application of Internal Revenue Code Section 409A. If the Company determines that any of the severance benefits provided by this
Agreement in Section 5 fail to satisfy the distribution requirement of Section 409A(a)(2)(A) of the Internal Revenue Code as a result of Section 409A(a)(2)(B)(i) of the Internal Revenue Code, the payment of such benefit shall be
accelerated to the minimum extent necessary so that the benefit is not subject to the provisions of Section 409A(a)(1) of the Internal Revenue Code. (It is the intention of the preceding sentence to apply the short-term deferral provisions of
Section 409A of the Internal Revenue Code, and the regulations and other guidance thereunder, to the Severance Benefits payments, and the payment schedule as revised after the application of the preceding sentence shall be referred to as the
“Revised Payment Schedule.”) However, if there is no Revised Payment Schedule that would avoid the application of Section 409A(a)(1) of the Internal Revenue Code, the payment of such benefits shall not be paid pursuant
to a Revised Payment Schedule and instead shall be delayed to the minimum extent necessary so that such benefits are not subject to the provisions of Section 409A(a)(1) of the Internal Revenue Code. The Board may attach conditions to or adjust
the amounts paid pursuant to Section 8(c) to preserve, as closely as possible, the economic consequences that would have applied in the absence of this Section 4.4.4; provided, however, that no such condition or adjustment shall
result in the payments being subject to Section 409A(a)(1) of the Internal Revenue Code. 
 (d) Parachute Payment. In the
event the benefits provided by this Agreement, when aggregated with any other payments or benefits received by you, would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for
this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be reduced to the Reduced Amount. The “Reduced Amount” shall be either
(x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account
all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Executive’s receipt, on an after-tax basis, of the greater amount of the Payment
notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount, reduction shall
occur in the following order unless the Executive elects in writing a different order (provided, however, that such election shall be subject to Company approval if made on or after the effective date of the event that triggers the Payment):
reduction of cash payments; cancellation of accelerated vesting of stock awards; reduction of employee benefits. In the event that acceleration of vesting of stock award compensation is to be reduced, such acceleration of vesting shall be cancelled
in the reverse order of the date of grant of Executive’s stock awards unless the Executive elects in writing a different order for cancellation. 

 Carlos Riva 
 June 20,
2007 
  

 The accounting firm engaged by the Company for general audit purposes as of the day prior to the
effective date of the Change of Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change of Control, then the
Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. 
 The accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the
Executive and the Company within fifteen (15) calendar days after the date on which the Executive’s right to a Payment is triggered (if requested at that time by the Executive or the Company) or such other time as requested by the
Executive or the Company. If the accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Executive and the Company with an opinion
reasonably acceptable to the Executive that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Executive and the Company.

 8. Continuation of Employment. You understand, acknowledge and agree that this Agreement does not create an obligation for
the Company or any other person to continue your employment and, subject to your right to receive compensation and benefits as provided in Section 5, you will be an at-will employee and the Company may terminate your employment at any time
subject to any notice provisions set forth in this Agreement. 
 9. Choice of Law. This Agreement, and all disputes arising
under or related to it, shall be governed by the law of the Commonwealth of Massachusetts. 
 10. Arbitration. All disputes
arising out of this Agreement (other than initial applications for injunctive relief under the Employee Invention Agreement) shall be resolved by final and binding arbitration. The arbitration shall be conducted in Boston, Massachusetts under the
American Arbitration Association’s (“AAA”) National Rules for the Resolution of Employment Disputes employing a single arbitrator selected upon mutual agreement of the parties. The arbitrator will have the power to award
any types of legal or equitable relief that would be available in a court of competent jurisdiction, including an award of attorneys’ fee and costs to the prevailing party. Each party will be responsible for their own costs and attorney’s
fees, other than the costs for AAA and the single arbitrator, which shall be borne by the Company. 
 11. Assignment. This
Agreement, and the rights and obligations of you and the Company hereunder, shall inure to the benefit of and shall be binding upon, you, your heirs and representatives, and upon the Company and the Company’s successors and assigns. This
Agreement may not be assigned by you. Any assignment in contravention of this Section 12 shall be null and void. 

 Carlos Riva 
 June 20,
2007 
  

 12. Severability. In the event that any one or more of the provisions of this Agreement
shall be held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. Moreover, if any one or more of the provisions contained in this
Agreement shall be held to be excessively broad as to duration, activity or subject, such provision shall be construed by limiting or reducing them so as to be enforceable to the maximum extent compatible with applicable law. 
 13. Consultation with Counsel; No Representations. You agree and acknowledge that you have had a full and complete opportunity to consult
with counsel of your own choosing concerning the terms, enforceability and implications of this Agreement. Both you and the Company acknowledge that neither party has made any representations or warranties to the other party concerning the terms,
enforceability or implications of this Agreement other than as are reflected in this Agreement. 
 14. No Mitigation; No Set
Off. In the event of any termination of employment hereunder, you shall be under no obligation to seek other employment and there shall be no offset against any amounts due to you under this Agreement on account of any remuneration
attributable to any subsequent employment that you may obtain. 
 15. Company Representations. The Company represents and
warrants that it is duly authorized to enter into this Agreement, that there is no law, agreement or other legal restriction on its entering into this Agreement, that its Board has approved this Agreement and that the officer signing this Agreement
is duly authorized and empowered to sign this Agreement on behalf of the Company 
 16. Effect of Agreement on Other Benefits.
Except as specifically provided in this Agreement, the existence of this Agreement shall not prohibit or restrict your entitlement to full participation in the employee benefit and other plans or programs in which comparable senior executives of the
Company are eligible to participate. 
 17. Integration. This Agreement and the documents attached hereto set forth the entire
agreement of the parties hereto in respect of the subject matter contained herein and therein and supersedes all prior and contemporaneous conflicting agreements, promises, covenants, arrangements, understandings, communications, representations or
warranties, whether oral or written, by any party hereto (or representative of either party hereto). 
 18. Modification;
Waiver. No provision of this Agreement may be modified, amended, waived or discharged unless such waiver, modification, amendment or discharge is agreed to in writing and signed by you and the Chairman of the Board. No waiver by either party
hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the
same or at any prior or subsequent time. 

 Carlos Riva 
 June 20,
2007 
  

 If the foregoing correctly conforms to your understanding of the agreement between you and Company,
please sign and date the enclosed copy of this letter and return it to us. 
  

									
		 		 	Very truly yours,	 	
				
		 		 	DIVERSA CORPORATION	 	
					
		 		 	By:	 	 /s/ JIM CAVANAUGH
	 	
		 		 	Name:	 	 Jim Cavanaugh
	 	
		 		 	Title:	 	 Chairman of the Board
	 	
	Agreement Confirmed:	 		 		 		 	
					
	 /s/ CARLOS RIVA
	 		 		 		 	
	CARLOS RIVA	 		 		 		 	

 EXHIBIT A 
 RELEASE AND WAIVER OF CLAIMS 
 TO BE SIGNED FOLLOWING TERMINATION WITHOUT CAUSE OR 

RESIGNATION FOR GOOD REASON 
 In
consideration of the payments and other benefits set forth in Section 5 of the Employment Agreement dated June 20, 2007, to which this form is attached, I, CARLOS RIVA, hereby furnish
DIVERSA CORPORATION (the “Company”), with the following release and waiver (“Release and Waiver”). 
 In exchange for the consideration provided to me by the Employment Agreement that I am not otherwise entitled to receive, I hereby generally and
completely release the Company and its directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, Affiliates, and assigns from any and all claims, liabilities and
obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to my signing this Release and Waiver. This general release includes, but is not limited to: (1) all claims
arising out of or in any way related to my employment with the Company or the termination of that employment; (2) all claims related to my compensation or benefits from the Company, including, but not limited to, salary, bonuses, commissions,
vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (3) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good
faith and fair dealing; (4) all tort claims, including, but not limited to, claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (5) all federal, state, and local statutory claims, including,
but not limited to, claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age
Discrimination in Employment Act of 1967 (as amended) (“ADEA”), the federal Employee Retirement Income Security Act, the California Fair Employment and Housing Act (as amended), the Massachusetts Fair Employment Practice Act,
the Massachusetts law prohibiting age discrimination, the Massachusetts Equal Rights Act, the Massachusetts Sexual Harassment law, and the Massachusetts Equal Pay Law. 
 I acknowledge that, among other rights, I am waiving and releasing any rights I may have under ADEA, that this Release and Waiver is knowing and voluntary, and that the consideration given for this Release and Waiver
is in addition to anything of value to which I was already entitled as an executive of the Company. If I am 40 years of age or older upon execution of this Release and Waiver, I further acknowledge that I have been advised, as required by the Older
Workers Benefit Protection Act, that: (a) the release and waiver granted herein does not relate to claims under the ADEA which may arise after this Release and Waiver is executed; (b) I should consult with an attorney prior to executing
this Release and Waiver; (c) I have twenty-one (21) days in which to consider this Release and Waiver (although I may choose voluntarily to execute this Release and Waiver earlier); (d) I have seven (7) days following the
execution of this Release and Waiver to revoke my consent to this Release and Waiver; and (e) this Release and Waiver shall not be effective until the eighth day after I execute this Release and Waiver and the revocation period has expired.

 I acknowledge my continuing obligations under my Employee Invention and Non-Disclosure Agreement
(“NDA”). Pursuant to the NDA I understand that among other things, I must not use or disclose any confidential or proprietary information of the Company and I must immediately return all Company property and documents
(including all embodiments of proprietary information) and all copies thereof in my possession or control. I understand and agree that my right to the severance pay I am receiving in exchange for my agreement to the terms of this Release and Waiver
is contingent upon my continued compliance with the NDA. 
 This Release and Waiver constitutes the complete, final and exclusive embodiment
of the entire agreement between the Company and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company that is not expressly stated herein. This Release and Waiver may only be modified by a
writing signed by both me and a duly authorized officer of the Company. 
  

									
	Date:	 	 June 20, 2007
	 		 	By:	 	 /s/ CARLOS RIVA

		 		 		 		 	CARLOS RIVA

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}]]